Skip to main content
SpringerLink
Log in

Biomarkers in prostate cancer: new era and prospective

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Currently, most men are diagnosed with prostate cancer (PCa) after a prostate-specific antigen (PSA) test shows an elevated level of the PSA protein. An elevated level suggests cancer may be present. If an elevation is detected, a biopsy to detect cancer is followed. But the PSA test is controversial. An elevated level does not always mean there is cancer present. The test often leads men to having unnecessary biopsies and treatments. Even if cancer is found on biopsy, many of these cancers are slow growing and would not impact the lives of the men who have them. Current advances in molecular techniques have provided new tools facilitating the discovery of new biomarkers for PCa. The purpose of this review is to examine the advances in PCa biomarkers and implication for possible improving disease outcome. The future of cancer prognosis may rely on small panels of markers that can accurately predict PCa presence, stage, and metastasis and can serve as prognosticators, targets, and/or surrogate endpoints of disease progression and response to therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Cooperberg M, Vickers A, Broering J, Carroll P. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116:5226–34.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Lu-Yao G, Albertsen P, Moore D, Shih W, Lin Y, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Carter H, Albertsen P, Barry M, Etzioni R, Freedland S, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419–26.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Oberaigner W, Horninger W, Klocker H, Schönitzer D, Stühlinger W, et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164:376–84.

    Article  PubMed  Google Scholar 

  6. Darson M, Pacelli A, Roche P, Rittenhouse H, Wolfert R, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology. 1997;49:857–62.

    Article  CAS  PubMed  Google Scholar 

  7. Partin A, Mangold L, Lamm D, Walsh P, Epstein J, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–8.

    Article  CAS  PubMed  Google Scholar 

  8. Kattan M, Zelefsky M, Kupelian P, Scardino P, Fuks Z, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–9.

    CAS  PubMed  Google Scholar 

  9. Thompson I, Goodman P, Tangen C, Lucia M, Miller G, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.

    Article  CAS  PubMed  Google Scholar 

  10. Stamey T, Caldwell M, McNeal J, Nolley R, Hemenez M, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172(4):1297–301.

    Article  PubMed  Google Scholar 

  11. Sawyers CL. The cancer biomarker problem. Nature. 2008;452:548–52.

    Article  CAS  PubMed  Google Scholar 

  12. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, et al. The mutational landscape of prostate cancer. Eur Urol. 2013;64:567–76.

    Article  CAS  PubMed  Google Scholar 

  13. Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, et al. The genomic complexity of primary human prostate cancer. Nature. 2011;470:214–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Catalona W, Partin A, Sanda M, Wei J, Klee G, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml. Eur Urol. 2013;63:986–94.

    Article  CAS  PubMed  Google Scholar 

  16. Stacy L, William J. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014;6:74–7.

    Article  Google Scholar 

  17. Schalken J. Interview with Jack Schalken. PCA3 and its use as a diagnostic test in prostate cancer. Interview by Christine McKillop. Eur Urol. 2006;50:153–4.

    Article  PubMed  Google Scholar 

  18. Hessels D, Schalken J. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6:255–61.

    Article  CAS  PubMed  Google Scholar 

  19. Marks L, Bostwick D. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol. 2008;10:175–81.

    PubMed Central  PubMed  Google Scholar 

  20. Crawford E, Rove K, Trabulsi E, Qian J, Drewnowska KP, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726–31.

    Article  PubMed  Google Scholar 

  21. Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, et al. Clinical utility of a multiplexed epigenetic gene assay to detect cancer in histopathologically negative prostate biopsies: results of the multicenter MATLOC study. American Urological Association annual meeting. Atlanta, GA; 2012. Abstract LBA6.

  22. Trock B, Brotzman M, Mangold L, Bigley J, Epstein JI, et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 2012;110:56–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Kumar-Sinha C, Tomlins S, Tomlins S, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497–511.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, et al. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. Prostate Cancer Prostatic Dis. 2010;13:47–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Chaux A, Peskoe S, Gonzalez-Roibon N, Schultz L, Albadine R, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25:1543–9.

    Article  CAS  PubMed  Google Scholar 

  26. Reid A, Attard G, Ambroisine L, Fisher G, Kovacs G, et al. Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010;102:678–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Klein E, Maddala T, Millward C, Cherbavaz D, Falzarano S, et al. Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. Poster presentation at the American Society of Clinical Oncology annual meeting. Chicago, IL; 2012. Abstr 456.

  28. Klein E, Cooperberg M, Magi-Galluzzi C, Simko J, Falzarano S, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy under sampling. Eur Urol. 2014;. doi:10.1016/j.eururo.2014.05.004.

    Google Scholar 

  29. Cuzick J, Swanson G, Fisher G, Brothman AR, Berney DM, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013;4:600–9.

    PubMed Central  PubMed  Google Scholar 

  31. Karnes R, Bergstralh E, Davicioni E, Ghadessi M, Buerki C, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013;190:2047–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Chen C, Mahalingam D, Osmulski P, Jadhav R, Wang C, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013;73:813–26.

    Article  PubMed  Google Scholar 

  33. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res. 2013;73:8–11.

    Article  CAS  PubMed  Google Scholar 

  34. Shariat S, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A, et al. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50(1):61–75.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim Biophys Acta. 2014;1846:99–112.

    PubMed  Google Scholar 

  36. Diamandis PE. Early prostate cancer antigen-2: a controversial prostate cancer biomarker? Clin Chem. 2010;56(4):542–4.

    Article  CAS  PubMed  Google Scholar 

  37. Steuber T, Vickers A, Haese A, Kattan M, Eastham J, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. 2007;120:1499–504.

    Article  CAS  PubMed  Google Scholar 

  38. Shariat S, Kattan M, Traxel E, Andrews B, Zhu K, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992–9.

    Article  CAS  PubMed  Google Scholar 

  39. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12(1):109–17.

    Article  CAS  PubMed  Google Scholar 

  41. Kumar A, Jagtap D, Mahale S, Kumar M. Crystal structure of prostate secretory protein PSP94 shows an edge-to-edge association of two monomers to form a homodimer. J Mol Biol. 2010;397(4):947–56.

    Article  CAS  PubMed  Google Scholar 

  42. Elgamal A, Holmes E, Su S, Tino W, Simmons S, et al. Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol. 2000;18:10–6.

    Article  CAS  PubMed  Google Scholar 

  43. Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizokami I, Li L, et al. Serum antibodies to huntingtin interacting protien-1: a new blood test for prostate cancer. Cancer Res. 2005;65:4126–33.

    Article  CAS  PubMed  Google Scholar 

  44. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20:833–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors certify that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Oncology Center, King Abdullah Medical City-Holy Capital, Muzdallifa Streat, P.O. Box 57657, Mecca, 21995, Saudi Arabia

    Amrallah A. Mohammed

  2. Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Amrallah A. Mohammed

Authors
  1. Amrallah A. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amrallah A. Mohammed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammed, A.A. Biomarkers in prostate cancer: new era and prospective. Med Oncol 31, 140 (2014). https://doi.org/10.1007/s12032-014-0140-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0140-3

Keywords

Search

Navigation